MUTHOOTFIN: Gold loan structural tailwinds and regulatory support underpin 18–22% AUM growth, but earnings quality hinges on NPA recovery sustainability and opex discipline; margins face 50–100 bps compression if cost inflation outpaces revenue, while competitive and macro risks cap upside to low-teens EPS growth.
📊 Base Case (50% Probability)
Key Variables: Gold prices stable (±5%), MCLR pass-through in H2, regulated branch growth.
Outcome: AUM grows 18–22%, NIM stable at ~7.5% (recoveries offset funding lag). Opex growth moderates to 15%, margins 26–28%. EPS grows 8–12%, driven by gold loan dominance and subsidiary turnarounds. Guidance clarity supports valuation rerating.
ZYDUSLIFE’s topline: 12–15% CAGR driven by US specialty, India chronic portfolio, and International Markets; Bottomline: 8–10% EPS growth contingent on margin stability and R&D efficiency; Margins: 23–25% EBITDA range, with upside from biosimilar scaling and downside from acquisition dilution.
📊 Base Case (50% Probability)
DIVISLAB’s growth relies on CS (57% mix), with generics resilient but pressured by pricing. Bottomline depends on CS commercialization (CY27) and cost pass-through, while margins face labor/raw material volatility, partly offset by backward integration and automation over 2–3 years.
📊 Base Case (50% Probability)
Key Variables: (1) 2/3 CS projects commercialize in Q3–Q4 CY27; (2) Generic pricing stabilizes (China’s rebate removal lifts API prices by 3–5%). Outcome: Revenue 8–10% CAGR, EBITDA margins expand 50 bps (CS mix shift), and gross asset turnover improves to 1.4x by FY28. EPS grows 8–12% annually.
Continue reading “DIVISLAB – Q3 FY26 Earnings Call – 11-Feb-26”MAZDOCK’s topline: Structural defense tailwinds and order book visibility support 8–12% revenue CAGR, but execution risks cap upside; bottomline: EBITDA margins likely range-bound at 16–18% barring supply chain shocks; dividends: Sustainable at current payout ratios but vulnerable to capex trade-offs for next-gen projects.
📊 Base Case (50% Probability)
Key Variables: (1) P17A/MPV deliveries on schedule; (2) MOD budget grows at 8–10% annually.
Outcome: Revenue CAGR of 8–10%, margins stable at 16–18%. Dividend growth tracks earnings (₹8–10/share annually). FX neutrality assumed.
INDHOTEL: Findings imply sustained double-digit topline growth (12%–14%) with EBITDA margins at 39%–40% and PAT expansion (15%–18%), contingent on RevPAR resilience, acquisition execution, and capex discipline—structural diversification and asset-light scaling remain key differentiators.
📊 Base Case (50% Probability)
TORNTPHARM’s base case projects 12–14% CAGR driven by Brazil/U.S. execution and JB integration, with margins expanding to 33–34% by FY29. Outcomes hinge on GLP-1 timing, Germany resolution, synergy capture, and cost discipline, as structural tailwinds offset cyclical pricing pressures
📊 Base Case (50% Probability)
VBL’s topline hinges on weather normalization and Twizza execution, with 10–15% growth probable; bottomline leverages operating scale and cost absorption, targeting 12–20% EPS upside; margins face cyclical realization pressure but structural backward integration supports 23–26% India EBITDA and 17–20% ex-India EBITDA by 2027.
📊 Base Case (50% Probability)
Motherson FY27 outlook: Revenue growth (8–15%) depends on Greenfield execution and European OEM strength; consumer electronics/aerospace scalability is pivotal. EBITDA margins may swing 50–200 bps from commodity/FX, but efficiencies and ROCE discipline cushion downside. Non-auto expansion (40%+ ROCE) offsets auto cyclicality if execution succeeds.
📊 Base Case (50% Probability)
Key Variables: (1) European OEMs stabilize market share; (2) Greenfields contribute 70% of targeted FY27 revenue; (3) consumer electronics/aerospace scale to 20M units/year by FY28.
Outcome: Revenue grows 10–12% YoY in FY27; EBITDA margins expand 50–100 bps on operational efficiencies and FX tailwinds. Leverage remains 1.0–1.2x; ROCE in new ventures hits 35–40%. Implication: Sustainable topline growth; margin expansion offsets cyclical pressures.
BRITANNIA’s revenue may rise 8–10%, driven by e-commerce and adjacencies, though GST shifts and regional rivals weigh near term. Profit growth depends on commodity stability and margin discipline, with EBITDA at 19–21% if brand spend is balanced; gross margins volatile at 40–44%.
📊 Base Case (50% Probability)
Key Variables: (1) GST transition completes by Q1 FY27, (2) Commodity stability (flour/RPO ±5%).
Outcome: Revenue growth stabilizes at 8–10% (volume +5%, GST tailwinds +3–4%). Gross margins sustain at 42–44%; EBITDA margins hold at 19–21% with disciplined brand spend. Adjacencies grow at 20%+ (e-comm penetration reaches 12% by FY27). Cheese shows early turnaround signs; state incentives partially offset. Labor Code costs contained.
Pidilite’s revenue growth of 9–11% CAGR (base) driven by domestic resilience and adhesive penetration, with ±3% export variance. PAT CAGR at 12–15% (base) on 24–25% margins; bull case hinges on EU trade deal, bear case on shocks. EBITDA corridor: 20–24%.
📊 Base Case (50% Probability)
Key Variables: (1) U.S. tariffs resolved by Q1 FY27 (exports flat YoY); (2) Tile adhesive penetration sustains 15–18% CAGR; (3) A&SP delivers +50 bps UVG uplift.
Outcome: Revenue growth 9–11%, EBITDA margin 24–25% (gross margin tailwinds offset by A&SP). Dr. Fixit/Roff outperform; pioneering segments contribute <5% revenue. Valuation supports 20–22x PE, in line with historical premium.